Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved diseases, particularly those related to immunological regulation. With a robust pipeline of proprietary drug candidates, Avalo is dedicated to addressing critical unmet medical needs in areas where effective treatments remain scarce. Leveraging in-depth insights into disease mechanisms alongside a rigorous clinical trial methodology, the company is well-positioned to achieve significant advancements in patient care. Through its patient-centric approach, Avalo not only seeks to improve therapeutic outcomes but also aims to make a substantial impact on the lives of those it serves, establishing itself as a noteworthy player in the biopharmaceutical landscape.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$17.18
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 6, 2026 | $-0.66 | $-0.83 | Miss -25.8% | $-0.83 | $0 | $0 | — | 1D Pre+1.7% | On-Day-0.7% | 1D Post-2.0% |
Q ended Mar 31, 2026 Reported May 13, 2026 | $-1.03 | $-0.98 | Beat +4.9% | $-0.98 | $0 | $0 | — | 1D Pre-1.5% | On-Day-0.5% | 1D Post-4.2% |
Q ended Dec 31, 2025 Reported Mar 23, 2026 | $-1.49 | $-0.37 | Beat +75.2% | |||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $0 |
| $59K |
| — |
| 1D Pre-5.6% |
| On-Day+0.6% |
| 1D Post-0.4% |
Q ended Sep 30, 2025 Reported Nov 6, 2025 | $-1.22 | $-2.19 | Miss -79.5% | — | $0 | — | — | 1D Pre+2.2% | On-Day-6.3% | 1D Post-2.4% |